Condition: Primary Hyperaldosteronism · Sponsor: AstraZeneca
This is a Phase III, multicentre, randomised, double-blind, placebo-controlled, parallel-group study to evaluate the safety, tolerability, and efficacy of baxdrostat versus placebo, on the reduction of Seated Blood Pressure (SBP) and achieving normalization of the Renin Angiotensin Aldosterone System (RAAS) in approximately 250 participants ≥ 18 years of age with Primary Aldosteronism (PA), with or without prior treatment with Mineralocorticoid Receptor Antagonists (MRAs) or potassium-sparing diuretics. Baxdrostat (or placebo) will be administered once daily, up-titrated after 2 weeks based on clinical response and tolerability. The study is planned to be conducted globally in approximately 90 study centres and 12 countries.
This description comes directly from the study's public registry record.
AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com
Always discuss trial participation with your own doctor first.
| Research Site | Los Angeles, California, United States | Withdrawn |
| Research Site | San Francisco, California, United States | Active Not Recruiting |
| Research Site | Farmington, Connecticut, United States | Active Not Recruiting |
| Research Site | Chicago, Illinois, United States | Recruiting |
| Research Site | Springfield, Illinois, United States | Active Not Recruiting |
| Research Site | Baltimore, Maryland, United States | Active Not Recruiting |
| Research Site | Boston, Massachusetts, United States | Active Not Recruiting |
| Research Site | Boston, Massachusetts, United States | Active Not Recruiting |
| Research Site | Ann Arbor, Michigan, United States | Active Not Recruiting |
| Research Site | Rochester, Minnesota, United States | Active Not Recruiting |
| Research Site | Olive Branch, Mississippi, United States | Recruiting |
| Research Site | Kansas City, Missouri, United States | Withdrawn |
+ 77 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07007793